118 related articles for article (PubMed ID: 10226617)
1. Effect of nucleoside analogs and non-nucleoside inhibitors of HIV-1 reverse transcriptase on cell-free virions.
Ventura M; Tarrago-Litvak L; Dollé V; Nguyen CH; Legraverend M; Fleury HJ; Litvak S
Arch Virol; 1999; 144(3):513-23. PubMed ID: 10226617
[TBL] [Abstract][Full Text] [Related]
2. Potent inhibition of human immunodeficiency virus type 1 replication by template analog reverse transcriptase inhibitors derived by SELEX (systematic evolution of ligands by exponential enrichment).
Joshi P; Prasad VR
J Virol; 2002 Jul; 76(13):6545-57. PubMed ID: 12050367
[TBL] [Abstract][Full Text] [Related]
3. Kinetic analysis of intravirion reverse transcription in the blood plasma of human immunodeficiency virus type 1-infected individuals: direct assessment of resistance to reverse transcriptase inhibitors in vivo.
Zhang H; Dornadula G; Wu Y; Havlir D; Richman DD; Pomerantz RJ
J Virol; 1996 Jan; 70(1):628-34. PubMed ID: 8523584
[TBL] [Abstract][Full Text] [Related]
4. Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV.
Witvrouw M; Pannecouque C; Van Laethem K; Desmyter J; De Clercq E; Vandamme AM
AIDS; 1999 Aug; 13(12):1477-83. PubMed ID: 10465070
[TBL] [Abstract][Full Text] [Related]
5. Three-drug combinations of emivirine and nucleoside reverse transcriptase inhibitors in vitro: long-term culture of HIV-1-infected cells and breakthrough viruses.
Nitanda T; Wang X; Somekawa K; Yuasa S; Baba M
Antivir Chem Chemother; 2001 May; 12(3):161-7. PubMed ID: 12959324
[TBL] [Abstract][Full Text] [Related]
6. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.
Miller V; Larder BA
Antivir Ther; 2001; 6 Suppl 3():25-44. PubMed ID: 11678471
[TBL] [Abstract][Full Text] [Related]
7. Antiviral activity of 4-benzyl pyridinone derivatives as HIV-1 reverse transcriptase inhibitors.
Andreola ML; Nguyen CH; Ventura M; Tarrago-Litvak L; Legraverend M
Expert Opin Emerg Drugs; 2001 Oct; 6(2):225-38. PubMed ID: 15989523
[TBL] [Abstract][Full Text] [Related]
8. Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors.
Domaoal RA; Demeter LM
Int J Biochem Cell Biol; 2004 Sep; 36(9):1735-51. PubMed ID: 15183341
[TBL] [Abstract][Full Text] [Related]
9. Perspectives on the molecular mechanism of inhibition and toxicity of nucleoside analogs that target HIV-1 reverse transcriptase.
Anderson KS
Biochim Biophys Acta; 2002 Jul; 1587(2-3):296-9. PubMed ID: 12084471
[TBL] [Abstract][Full Text] [Related]
10. The level of reverse transcriptase (RT) in human immunodeficiency virus type 1 particles affects susceptibility to nonnucleoside RT inhibitors but not to lamivudine.
Ambrose Z; Julias JG; Boyer PL; Kewalramani VN; Hughes SH
J Virol; 2006 Mar; 80(5):2578-81. PubMed ID: 16474164
[TBL] [Abstract][Full Text] [Related]
11. Excision of nucleoside analogs from DNA by p53 protein, a potential cellular mechanism of resistance to inhibitors of human immunodeficiency virus type 1 reverse transcriptase.
Bakhanashvili M; Novitsky E; Rubinstein E; Levy I; Rahav G
Antimicrob Agents Chemother; 2005 Apr; 49(4):1576-9. PubMed ID: 15793143
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptase.
Menéndez-Arias L
Virus Res; 2008 Jun; 134(1-2):124-46. PubMed ID: 18272247
[TBL] [Abstract][Full Text] [Related]
13. The effect of NNRTIs on HIV reverse transcriptase dimerization.
Tachedjian G; Goff SP
Curr Opin Investig Drugs; 2003 Aug; 4(8):966-73. PubMed ID: 14508881
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and evaluation of "AZT-HEPT", "AZT-pyridinone", and "ddC-HEPT" conjugates as inhibitors of HIV reverse transcriptase.
Pontikis R; Dollé V; Guillaumel J; Dechaux E; Note R; Nguyen CH; Legraverend M; Bisagni E; Aubertin AM; Grierson DS; Monneret C
J Med Chem; 2000 May; 43(10):1927-39. PubMed ID: 10821705
[TBL] [Abstract][Full Text] [Related]
15. HIV-1-specific RT inhibitors: highly selective inhibitors of human immunodeficiency virus type 1 that are specifically targeted at the viral reverse transcriptase.
De Clercq E
Med Res Rev; 1993 May; 13(3):229-58. PubMed ID: 7683360
[TBL] [Abstract][Full Text] [Related]
16. The reverse transcriptase codon 69 insertion is observed in nucleoside reverse transcriptase inhibitor-experienced HIV-1-infected individuals, including those without prior or concurrent zidovudine therapy.
Ross L; Johnson M; Graham N; Shaefer M; St Clair M
J Hum Virol; 1999; 2(5):290-5. PubMed ID: 10551735
[TBL] [Abstract][Full Text] [Related]
17. Morphologic changes in human immunodeficiency virus type 1 virions secondary to intravirion reverse transcription: evidence indicating that reverse transcription may not take place within the intact viral core.
Zhang H; Dornadula G; Orenstein J; Pomerantz RJ
J Hum Virol; 2000; 3(3):165-72. PubMed ID: 10881997
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and anti-HIV activities of unsymmetrical long chain dicarboxylate esters of dinucleoside reverse transcriptase inhibitors.
Agarwal HK; Chhikara BS; Doncel GF; Parang K
Bioorg Med Chem Lett; 2017 May; 27(9):1934-1937. PubMed ID: 28351588
[TBL] [Abstract][Full Text] [Related]
19. The development of HEPT-type HIV non-nucleoside reverse transcriptase inhibitors and its implications for DABO family.
Chen W; Zhan P; Wu J; Li Z; Liu X
Curr Pharm Des; 2012; 18(27):4165-86. PubMed ID: 22621244
[TBL] [Abstract][Full Text] [Related]
20. [Establishment of pharmacological evaluation system for non-nucleoside reverse-transcriptase inhibitors resistant HIV-1].
Cao YL; Li SX; Chen H; Guo Y
Yao Xue Xue Bao; 2009 Apr; 44(4):355-61. PubMed ID: 19545051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
